Pernix Therapeutics (PTX) Shifiting To Offense, Needham & Company Says
Tweet Send to a Friend
Needham & Company analyst Elliot Wilbur reiterated a Buy rating and $6.30 price target on Pernix Therapeutics (NASDAQ: PTX) saying ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
